Extension Study to Study PQ-110-001 (NCT03140969)

Summary

Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.

Timeline

Start

2019-05-13

Primary completion

2022-10-03

Completion

2022-10-03

Outcome

Outcome not reported

Stopped (Business): “Terminated \[Study prematurely terminated due to sponsor decision for reasons unrelated to safety\]”

Drugs

Indications